HomeBUSINESS
BUSINESS

Gilead Aiming to Develop World’s First NASH Treatment, Hoping for Approval in 2020
(Dec.20.2017)

Gilead Sciences is now focused on developing treatments for non-alcoholic steatohepatitis (NASH) as new drugs to succeed its hepatitis C treatments Harvoni (ledipasvir + sofosbuvir) and Sovaldi (sofosbuvir). Selonsertib, an apoptosis signal-regulating kinase 1 (ASK1) inhibitor, is currently undergoing multinational PIII trials. Gilead aims to file for approval in Japan and other countries in the latter half of 2019 and to obtain approval in 2020. Gilead aims to turn its product into a blockbuster by obtaining the world’s first approval. Masayuki Omote, head of clinical development Japan, talked about the company’s plans in a recent interview with Jiho ...
(LOG IN FOR FULL STORY)